Telescope Innovations Corp., a chemical technology company, develops manufacturing processes and tools for the pharmaceutical and chemical industry in the United States and Canada. It offers DIRECTINJECT-LCTM, a hardware and software ecosystem that enables direct sampling and analysis of chemical reactions. It also provides intellectual property and contract research services. It serves pharmaceutical, critical minerals, and chemical industries. Telescope Innovations Corp. has a research collaboration with Pfizer Inc; and Standard Lithium Ltd. to develop a method for producing high-purity lithium sulfide. Telescope Innovations Corp. has a development and collaboration agreement with AGI Group's Synthesis, Digitization, and Automation program to develop the next generation of automation- and AI-ready chemical reactor technology. Telescope Innovations Corp. is based in Vancouver, Canada.…
Senior Canadian Officials and Diplomatic Leaders Tour the Self-Driving Lab Provided by Telescope Innovations to KPBMA in South Korea
Telescope Innovations (CNSX: TELI) is listed on the Canadian Securities Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 0.2400 CAD on 20 November 2026, down 37.7% over 52 weeks. Its 52-week range is 0.2400 CAD to 1.100 CAD, and it trades at the bottom of that range.
Its market capitalisation is 19.39M CAD.
Telescope Innovations reports return on equity of -78.0%, an operating margin of -51.4% and revenue up 18.4% year over year.
Its debt exceeds its cash by 1.38M CAD, a debt-to-equity ratio of 1.73. Its Piotroski F-score is 5 out of 9, an average reading of its financial health.
No upcoming events tracked.